Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings is a commercial-stage biotechnology company with a diverse pipeline of drug candidates in various therapeutic areas. Their main product, KIMMTRAK, is currently the standard of care treatment for a rare type of melanoma, and the company's other drug candidates show promise in treating various oncology, infectious, and autoimmune diseases. Additionally, their use of advanced technology and strong partnerships position them for future success and potential value creation. Although there are risks involved in the clinical development and commercialization process, Immunocore's current market presence and potential for growth make them a promising investment opportunity.

Bears say

Immunocore Holdings is facing significant risk in its stock outlook due to high competition in the biotechnology industry and its lack of diversity in its product pipeline. With only one commercial product, KIMMTRAK, and a pipeline still in early stages of development, the company is heavily dependent on the success of its current product. Additionally, with a track record of negative earnings and decreasing cash flows, the company's financial health and potential for future growth seem uncertain.

Immunocore Holdings (IMCR) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 8 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Sep 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.